Surgery – Means for introducing or removing material from body for... – With means for cutting – scarifying – or vibrating tissue
Reexamination Certificate
2000-01-26
2003-10-21
Casler, Brian L. (Department: 3763)
Surgery
Means for introducing or removing material from body for...
With means for cutting, scarifying, or vibrating tissue
C604S264000
Reexamination Certificate
active
06635027
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates generally to methods and apparatus for delivering a substance, e.g. a drug or therapeutic or diagnostic agent, into the wall of a blood vessel or other body duct or vessel from the lumen of the vessel through application of a fine spray or mist of the substance at a high velocity from a plurality of infusion holes distributed around a relatively short infusion segment of an infusion catheter body.
BACKGROUND OF THE INVENTION
The above-reference parent patent sets forth a discussion of the delivery of thrombolytic agents including plasminogen activators and heparin compounds through various types of catheters to dissolve blood clots or thrombi in native blood vessels and in vascular grafts and dialysis grafts. Such plasminogen activators include streptokinase, urokinase and tissue plasminogen activator (t-PA) and their analogues have been administered as lytic agents for lysis of arterial and venous thromboses. Such thrombolytic agents are delivered within the lumen of native blood vessels and in vascular grafts and dialysis grafts and that discussion is incorporated herein by reference.
Catheters have also been described that are designed to be employed to locally deliver a drug or therapeutic or diagnostic agent intramurally, that is into the wall of a blood vessel or other body duct or vessel, from the lumen of the vessel. Systemic administration of drugs treats the organism as a whole, even though the disease may be localized, such as injury to a body duct or vessel wall. Vessel walls are lined by a smooth lumen surface referred to as the endothelial layer that improves vascular blood flow hemodynamics and shields deeper vessel wall layers from contact with body fluids, e.g., blood in a blood vessel. Localized delivery of a drug intramurally into organ cavity walls, duct walls and blood vessel walls from the organ cavity or duct or vessel lumen poses special problems, since, by nature, the endothelial layers of such walls serve to transport and/or contain fluids within the organ cavity or duct or vessel lumen or transport systems.
Atherosclerotic disease causes localized occlusion of the blood vessels resulting from the build-up of plaque, and certain occlusion clearing treatment procedures and equipment can cause unintended injury to the blood vessel wall. Plaque deposits on an arterial wall effectively reduces the artery diameter and impede blood circulation past the deposits. Percutaneous transluminal coronary angioplasty (PTCA), or simply angioplasty, has proven to be a useful procedure for the treatment of localized atherosclerotic lesions (plaque deposits) of both coronary and peripheral vessels. Angioplasty involves the insertion of catheters, such as balloon catheters, through the occluded region of the blood vessel in order to mechanically expand a lumen through the occluded region by expansion of the balloon. A wide variety of atherectomy devices have also been proposed to open an occlusion and abrade or cut away the plaque deposits.
Unfortunately, successful atherectomy and PTCA invariably involves some interruption of the endothelial lining with a resulting violation of the barrier it provides between the deeper placed intima and smooth muscle cells (SMC) of the vessel wall and the blood itself. Local hemodynamic flow characteristics are also affected. The mechanical abrasion of the intima and the proliferation of smooth muscle cells stimulated by the atherectomy or PTCA procedure is believed to be responsible for restenosis, or closing of the vessel lumen that sometimes occurs. Restenosis may also occur as a result of clot formation due to an atherectomy or PTCA procedure caused injury to the vessel wall which triggers the natural clot-forming reactions of the blood.
It has been proposed that one method of combating restenosis might be the administration of various therapeutic agents known to block intimal and smooth muscle hyperplasia. The typical methods of intravascular medication involve the delivery of the medication systemically, either intravenously, or regionally (e.g., by intracoronary infusion). Systemic delivery is usually ill-suited to the treatment of conditions occurring at one or more discrete sites, because it involves the delivery of the medication to sites other than the target site, and it requires the infusion of large doses of the medication to assure the delivery of a therapeutic dose to the target site, thereby creating the possibility of deleterious effects. Another problem of systemic administration is the inevitable fluctuations of serum drug concentrations that it produces. The dosage that can be delivered to the target site may be limited by the need to minimize unwanted effects in other parts of the body. Furthermore, systemic delivery exposes the medication to possible degradation and elimination by the action of other bodily organs. For these reasons, systemically administered drugs such as anticoagulants, vasodilator, etc. have so far proven ineffective to prevent restenosis. More radical treatment involving agents such as cytostatic drugs or general enzyme blockers may prevent smooth muscle cell proliferation, but often these agents are toxic to humans at the levels necessary to effectively block development of the involved pathology.
Recently, site-specific drug delivery to the arterial wall has become a new strategy for the treatment of vascular diseases, including vessel restenosis following PTCA or atherectomy. These drug delivery systems include: (1) intravascular devices for site-specific (coronary artery) drug delivery comprising double-balloon catheters, porous balloon catheters, microporous balloon catheters, channel balloon catheters, balloon over stent catheters, hydrogel coated balloon catheters, iontophoretic balloon catheters and stent devices; (2) periadventitial and epicardial drug delivery devices, requiring surgical implantation, which include drug-eluting polymer matrices and a iontophoretic patch device; and (3) intramural injection of drug-eluting microparticles. See, for example, the descriptions of such devices appearing in U.S. Pat. Nos. 5,900,433, 5,954,706 and 5,112,305.
Drug delivery catheters of the perforated balloon type are disclosed, for example, in U.S. Pat. Nos. 5,087,244, 5,112,305 and 5,344,402. Catheters of these types have some drawbacks. For example, because the same fluid is used as the balloon inflation medium and as the drug medium, dilatation by balloon expansion is necessarily accompanied by drug delivery; neither function can be performed independently, which may be disadvantageous or inefficient in various clinical situations. Further inefficiency is engendered by the expulsion of the therapeutic agent before the balloon is fully expanded, so that the agent is not as forcefully administered to the luminal wall tissue as it would be if the balloon were fully expanded so as to bring it into close proximity or contact with the wall. A related problem is that the agent is typically expelled at relatively low pressures that are insufficient to effect any substantial degree of penetration of the lumen wall surface, thereby limiting the therapeutic effect of the agent in certain situations. Finally, in drug delivery PTA catheters in which the same fluid is used as the balloon inflation medium and the drug medium, the reversal of fluid flow to deflate the balloon may tend to draw blood into the catheter lumen, requiring it to be withdrawn for purging or replacement after a single use.
Direct injection of drugs from infusion ports of a catheter against the endothelial layer and into the vessel wall have also been proposed in commonly assigned U.S. Pat. No. 5,554,114. A catheter body without a balloon is provided that can be advanced in a straight configuration to the injured or diseased vessel site of and then transformed into a loose, helical distal infusion segment having infusion ports arranged toward the vessel wall.
Thus, problems remain however in the exact method by which the local administration of drugs or therapeutic agents shoul
Cragg Andrew H.
Olson Edward L.
Breimayer Joseph F.
Casler Brian L.
Han Mark K.
Micro Therepeutics, Inc.
LandOfFree
Method and apparatus for intramural delivery of a substance does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and apparatus for intramural delivery of a substance, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and apparatus for intramural delivery of a substance will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3118869